Search Results - "Groenland, S.L."

Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients by Groenland, S.L., Geel, D.R., Janssen, J.M., Beijnen, J.H., Burgers, S.A., Smit, E.F., Huitema, A.D.R., Steeghs, N.

Get full text

1486PD - Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients by Groenland, S.L., Geel, D.R., Janssen, J.M., Beijnen, J.H., Burgers, S.A., Smit, E.F., Huitema, A.D.R., Steeghs, N.

“…Crizotinib and alectinib are first and second generation ALK-inhibitors, respectively, indicated for the treatment of ALK+ NSCLC. At the currently used fixed…”
Get full text

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study by Groenland, S.L., van Eerden, R.A.G., Westerdijk, K., Meertens, M., Koolen, S.L.W., Moes, D.J.A.R., de Vries, N., Rosing, H., Otten, H., Vulink, A.J.E., Desar, I.M.E., Imholz, A.L.T., Gelderblom, H., van Erp, N.P., Beijnen, J.H., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

“…Oral targeted therapies show a high pharmacokinetic (PK) interpatient variability. Even though exposure has been positively correlated with efficacy for many…”
Get full text

567P Exposure-response analyses of dabrafenib and trametinib in melanoma patients by Groenland, S.L., Janssen, J.M., Nijenhuis, C., de Vries, N., Rosing, H., Wilgenhof, S., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U., Beijnen, J., Huitema, A., Steeghs, N.

Get full text

Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study by Maio, M., Groenland, S.L., Bauer, T., Rischin, D., Gardeazabal, I., Moreno, V., Trigo Perez, J.M., Chisamore, M., Sadik Shaik, J., Rigat, F., Ellis, C., Chen, H., Gagnon, R., Scherer, S., Turner, D., Yadavilli, S., Ballas, M., Hoos, A., Angevin, E.

Get full text

Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study by Groenland, S.L., Van Eerden, R.A.G., Koolen, S.L., Moes, D J A R, Desar, I.M.E., Touw, D.J., Imholz, A.L.T., Reyners, A.K.L., Gelderblom, H., van Erp, N.P., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

Get full text

1971P - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study by Maio, M., Groenland, S.L., Bauer, T., Rischin, D., Gardeazabal, I., Moreno, V., Trigo Perez, J.M., Chisamore, M., Sadik Shaik, J., Rigat, F., Ellis, C., Chen, H., Gagnon, R., Scherer, S., Turner, D., Yadavilli, S., Ballas, M., Hoos, A., Angevin, E.

“…GSK609 an agonist non-T cell depleting IgG4 monoclonal antibody (mAb) against inducible co-stimulatory receptor (ICOS) exhibits T cell mediated immune…”
Get full text

442O - Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study by Groenland, S.L., Van Eerden, R.A.G., Koolen, S.L., Moes, D J A R, Desar, I.M.E., Touw, D.J., Imholz, A.L.T., Reyners, A.K.L., Gelderblom, H., van Erp, N.P., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

“…Oral anticancer drugs show a high interpatient variability in pharmacokinetics (PK). Even though exposure has been linked to efficacy and toxicity for many of…”
Get full text

1119PD - Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC) by Rischin, D., Groenland, S.L., Lim, A.M.L., Martin-Liberal, J., Moreno, V., Trigo Perez, J.M., Le Tourneau, C., Mathew, M., Cho, D.C., Hansen, A.R., Vincente-Baz, D., Maio, M., Italiano, A., Bauman, J.R., Chisamore, M., Zhou, H., Ellis, C., Ballas, M., Hoos, A., Angevin, E.

“…INDUCE-1 is a first in human study investigating GSK609 alone (mono) and in combination (combo) with other regimens including pembro. The study consists of…”
Get full text

Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC) by Rischin, D., Groenland, S.L., Lim, A.M.L., Martin-Liberal, J., Moreno, V., Trigo Perez, J.M., Le Tourneau, C., Mathew, M., Cho, D.C., Hansen, A.R., Vincente-Baz, D., Maio, M., Italiano, A., Bauman, J.R., Chisamore, M., Zhou, H., Ellis, C., Ballas, M., Hoos, A., Angevin, E.

Get full text

Incidence of clinically significant toxicities in patients with high endoxifen concentrations by Groenland, S.L., Sanchez-Spitman, A.B., Moes, D.J.A.R., Koolen, S.L., Dezentjé, V.O., van Erp, N., Mathijssen, R.H.J., Guchelaar, H.-J., Huitema, A.D.R., Steeghs, N.

Get full text